Keywords
Last Name
Institution

Eric Carter Bartee

Title
InstitutionMedical University of South Carolina
DepartmentMicrobiology and Immunology
AddressP.O. Box MSC 504
203
173 Ashley Ave.
Phone843-792-7522
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Dr. Bartee's research interests involve the study of virus-host interactions with particular focus on how these interactions can be used to improve therapy for cancer patients. He is interested in the study of a rabbit-specific poxvirus called myxoma virus and how it interacts with normal and cancerous hematopoietic cells. He is currently exploring whether the virus can be used as a frontline therapy to improve treatment of myeloma patients by directly identifying and eliminating myeloma in vivo, eliminating residual myeloma after chemotherapy or expelling myeloma from its protected bone marrow niches.
    Collapse keywords
    Molecular Virology, Oncolytic Virotherapy

    Collapse ORNG Applications 
    Collapse studies/trials

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Burton C, Bartee MY, Bartee E. Impact of Induced Syncytia Formation on the Oncolytic Potential of Myxoma Virus. Oncolytic Virother. 2019; 8:57-69. PMID: 31850282.
      View in: PubMed
    2. Burton C, Bartee E. Syncytia Formation in Oncolytic Virotherapy. Mol Ther Oncolytics. 2019 Dec 20; 15:131-139. PMID: 31890866.
      View in: PubMed
    3. Dwyer CJ, Knochelmann HM, Smith AS, Wyatt MM, Rangel Rivera GO, Arhontoulis DC, Bartee E, Li Z, Rubinstein MP, Paulos CM. Fueling Cancer Immunotherapy With Common Gamma Chain Cytokines. Front Immunol. 2019; 10:263. PMID: 30842774.
      View in: PubMed
    4. Bartee MY, Dryja PC, Bartee E. Chimeric tumor modeling reveals role of partial PDL1 expression in resistance to virally induced immunotherapy. J Immunother Cancer. 2019 01 16; 7(1):11. PMID: 30651147.
      View in: PubMed
    5. Burton C, Das A, McDonald D, Vandergrift WA, Patel SJ, Cachia D, Bartee E. Oncolytic myxoma virus synergizes with standard of care for treatment of glioblastoma multiforme. Oncolytic Virother. 2018; 7:107-116. PMID: 30538967.
      View in: PubMed
    6. Wolfe AM, Rahman M, McFadden DG, Bartee EC. Refinement and Successful Implementation of a Scoring System for Myxomatosis in a Susceptible Rabbit (Oryctolagus cuniculus) Model. Comp Med. 2018 08 01; 68(4):280-285. PMID: 30017020.
      View in: PubMed
    7. Bartee E. Potential of oncolytic viruses in the treatment of multiple myeloma. Oncolytic Virother. 2017; 7:1-12. PMID: 29503813.
      View in: PubMed
    8. Bartee E, Li Z. In vivo and in situ programming of tumor immunity by combining oncolytics and PD-1 immune checkpoint blockade. Exp Hematol Oncol. 2017; 6:15. PMID: 28546884.
      View in: PubMed
    9. Bartee MY, Dunlap KM, Bartee E. Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy. Cancer Res. 2017 06 01; 77(11):2952-2963. PMID: 28314785.
      View in: PubMed
    10. Bartee E, Bartee MY, Bogen B, Yu XZ. Systemic therapy with oncolytic myxoma virus cures established residual multiple myeloma in mice. Mol Ther Oncolytics. 2016; 3:16032. PMID: 27933316.
      View in: PubMed
    11. Bartee MY, Dunlap KM, Bartee E. Myxoma Virus Induces Ligand Independent Extrinsic Apoptosis in Human Myeloma Cells. Clin Lymphoma Myeloma Leuk. 2016 Apr; 16(4):203-12. PMID: 26803534.
      View in: PubMed
    12. Dunlap KM, Bartee MY, Bartee E. Myxoma virus attenuates expression of activating transcription factor 4 (ATF4) which has implications for the treatment of proteasome inhibitor-resistant multiple myeloma. Oncolytic Virother. 2015; 4:1-11. PMID: 27512665.
      View in: PubMed
    13. Bartee E, McFadden G. Cytokine synergy: an underappreciated contributor to innate anti-viral immunity. Cytokine. 2013 Sep; 63(3):237-40. PMID: 23693158.
      View in: PubMed
    14. Chan WM, Bartee EC, Moreb JS, Dower K, Connor JH, McFadden G. Myxoma and vaccinia viruses bind differentially to human leukocytes. J Virol. 2013 Apr; 87(8):4445-60. PMID: 23388707.
      View in: PubMed
    15. Bartee E, Meacham A, Wise E, Cogle CR, McFadden G. Virotherapy using myxoma virus prevents lethal graft-versus-host disease following xeno-transplantation with primary human hematopoietic stem cells. PLoS One. 2012; 7(8):e43298. PMID: 22905251.
      View in: PubMed
    16. Bartee E, Chan WM, Moreb JS, Cogle CR, McFadden G. Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus. Biol Blood Marrow Transplant. 2012 Oct; 18(10):1540-51. PMID: 22516053.
      View in: PubMed
    17. Madlambayan GJ, Bartee E, Kim M, Rahman MM, Meacham A, Scott EW, McFadden G, Cogle CR. Acute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro. Leuk Res. 2012 May; 36(5):619-24. PMID: 22341701.
      View in: PubMed
    18. Bais S, Bartee E, Rahman MM, McFadden G, Cogle CR. Oncolytic virotherapy for hematological malignancies. Adv Virol. 2012; 2012:186512. PMID: 22312362.
      View in: PubMed
    19. Bartee E, Eyster CA, Viswanathan K, Mansouri M, Donaldson JG, Früh K. Membrane-Associated RING-CH proteins associate with Bap31 and target CD81 and CD44 to lysosomes. PLoS One. 2010 Dec 02; 5(12):e15132. PMID: 21151997.
      View in: PubMed
    20. Villa NY, Bartee E, Mohamed MR, Rahman MM, Barrett JW, McFadden G. Myxoma and vaccinia viruses exploit different mechanisms to enter and infect human cancer cells. Virology. 2010 Jun 05; 401(2):266-79. PMID: 20334889.
      View in: PubMed
    21. McFadden G, Mohamed MR, Rahman MM, Bartee E. Cytokine determinants of viral tropism. Nat Rev Immunol. 2009 Sep; 9(9):645-55. PMID: 19696766.
      View in: PubMed
    22. Bartee E, McFadden G. Human cancer cells have specifically lost the ability to induce the synergistic state caused by tumor necrosis factor plus interferon-beta. Cytokine. 2009 Sep; 47(3):199-205. PMID: 19640730.
      View in: PubMed
    23. Bartee E, Mohamed MR, Lopez MC, Baker HV, McFadden G. The addition of tumor necrosis factor plus beta interferon induces a novel synergistic antiviral state against poxviruses in primary human fibroblasts. J Virol. 2009 Jan; 83(2):498-511. PMID: 18971273.
      View in: PubMed
    24. Wang F, Gao X, Barrett JW, Shao Q, Bartee E, Mohamed MR, Rahman M, Werden S, Irvine T, Cao J, Dekaban GA, McFadden G. RIG-I mediates the co-induction of tumor necrosis factor and type I interferon elicited by myxoma virus in primary human macrophages. PLoS Pathog. 2008 Jul 11; 4(7):e1000099. PMID: 18617992.
      View in: PubMed
    25. Bartee E, Mohamed MR, McFadden G. Tumor necrosis factor and interferon: cytokines in harmony. Curr Opin Microbiol. 2008 Aug; 11(4):378-83. PMID: 18595771.
      View in: PubMed
    26. Thibodeau J, Bourgeois-Daigneault MC, Huppé G, Tremblay J, Aumont A, Houde M, Bartee E, Brunet A, Gauvreau ME, de Gassart A, Gatti E, Baril M, Cloutier M, Bontron S, Früh K, Lamarre D, Steimle V. Interleukin-10-induced MARCH1 mediates intracellular sequestration of MHC class II in monocytes. Eur J Immunol. 2008 May; 38(5):1225-30. PMID: 18389477.
      View in: PubMed
    27. Bartee E, McCormack A, Früh K. Quantitative membrane proteomics reveals new cellular targets of viral immune modulators. PLoS Pathog. 2006 Oct; 2(10):e107. PMID: 17238276.
      View in: PubMed
    28. Hassink G, Kikkert M, van Voorden S, Lee SJ, Spaapen R, van Laar T, Coleman CS, Bartee E, Früh K, Chau V, Wiertz E. TEB4 is a C4HC3 RING finger-containing ubiquitin ligase of the endoplasmic reticulum. Biochem J. 2005 Jun 01; 388(Pt 2):647-55. PMID: 15673284.
      View in: PubMed
    29. Nerenberg BT, Taylor J, Bartee E, Gouveia K, Barry M, Früh K. The poxviral RING protein p28 is a ubiquitin ligase that targets ubiquitin to viral replication factories. J Virol. 2005 Jan; 79(1):597-601. PMID: 15596852.
      View in: PubMed
    30. Bartee E, Mansouri M, Hovey Nerenberg BT, Gouveia K, Früh K. Downregulation of major histocompatibility complex class I by human ubiquitin ligases related to viral immune evasion proteins. J Virol. 2004 Feb; 78(3):1109-20. PMID: 14722266.
      View in: PubMed
    31. Mansouri M, Bartee E, Gouveia K, Hovey Nerenberg BT, Barrett J, Thomas L, Thomas G, McFadden G, Früh K. The PHD/LAP-domain protein M153R of myxomavirus is a ubiquitin ligase that induces the rapid internalization and lysosomal destruction of CD4. J Virol. 2003 Jan; 77(2):1427-40. PMID: 12502858.
      View in: PubMed
    32. Früh K, Bartee E, Gouveia K, Mansouri M. Immune evasion by a novel family of viral PHD/LAP-finger proteins of gamma-2 herpesviruses and poxviruses. Virus Res. 2002 Sep; 88(1-2):55-69. PMID: 12297327.
      View in: PubMed
    Bartee's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description